Delta sleep-inducing peptide (DSIP) and orexin (hypocretin) represent opposing forces in sleep-wake regulation. DSIP promotes slow-wave sleep through GABAergic mechanisms, while orexin stabilizes wakefulness through excitatory signaling in arousal circuits. Understanding their complementary roles is essential for comprehending sleep architecture and developing sleep disorder therapeutics.
- Sequence: 9 amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)
- MW: 849 Da
- pI: ~3.5
- Structure: Flexible peptide, no stable secondary structure
- Discovery: Schoenenberger and Monnier in 1977
- Distribution: Hypothalamus, thalamus, brainstem
Two bioactive forms derived from prepro-orexin:
- Orexin A: 33 amino acids, disulfide bond (Cys6-Cys12), MW 3,562 Da
- Orexin B: 28 amino acids, linear, MW 2,937 Da
- Discovery: Sakurai in 1998
- Distribution: Lateral hypothalamus (exclusively)
DSIP’s receptor remains incompletely characterized:
- Binding site: G-protein coupled receptor (putative)
- Primary mechanism: GABAergic modulation
- Brain regions: Thalamus, hypothalamus, brainstem
- Selectivity: Non-selective across sleep circuits
Orexin A and B activate two well-characterized receptors:
| Receptor | Orexin A EC₅₀ | Orexin B EC₅₀ | Distribution |
|---|
| OX1R | ~20 nM | >1 µM | Lateral hypothalamus, locus coeruleus |
| OX2R | ~50 nM | ~50 nM | Tuberal hypothalamus, raphe nuclei |
OX1R selectively binds orexin A, while OX2R binds both orexins with similar affinity.
DSIP promotes sleep through multiple mechanisms:
- Thalamic modulation: Enhances thalamocortical oscillations (delta waves)
- GABAergic potentiation: Potentiates GABA-A receptor currents
- Thermoregulation: Reduces core body temperature
- ACTH modulation: Suppresses ACTH release (reduces arousal)
- Microinjection effects: Produces synchronized delta EEG activity
Effects on sleep architecture:
- Increases slow-wave sleep (SWS) by 30–50%
- Enhances delta power (0.5–4 Hz)
- Reduces sleep latency
- May reduce REM sleep at high doses
Orexin stabilizes wakefulness through excitatory signaling:
- Monoaminergic activation: Excites locus coeruleus (NE), raphe (5-HT), TMN (histamine)
- Cholinergic activation: Excites basal forebrain (ACh)
- Glutamatergic signaling: Direct excitatory effects on arousal neurons
- Metabolic sensing: Links energy status to wakefulness
- Reward circuits: Modulates dopamine in VTA
Effects on sleep architecture:
- Suppresses sleep transitions
- Stabilizes wake bouts
- Prevents inappropriate sleep episodes
- Maintains consolidated sleep-wake cycles
| Function | DSIP | Orexin |
|---|
| Sleep-wake regulation | Promotes SWS | Promotes wakefulness |
| Cortisol rhythm | Suppresses nocturnal cortisol | Stimulates CRH release |
| Thermoregulation | Reduces body temperature | Increases temperature |
| Feeding behavior | No direct effect | Stimulates appetite |
| Energy homeostasis | Minimal | Links sleep to metabolism |
| Stress response | Attenuates | Potentiates |
| Application | Evidence Level | Key Findings |
|---|
| Insomnia | Phase II | Reduced sleep latency, increased SWS |
| Jet lag | Phase II | Accelerated circadian adjustment |
| Withdrawal syndromes | Phase II | Reduced withdrawal symptoms |
| Pain modulation | Phase III | Adjunct in cancer pain |
| Aging-related sleep disruption | Phase II | Improved sleep quality |
| Application | Evidence Level | Key Findings |
|---|
| Narcolepsy (orexin deficiency) | Phase III | Orexin replacement under investigation |
| Insomnia (orexin antagonism) | Approved | Suvorexant, lemborexant |
| Wakefulness promotion | Approved | Modafinil (indirect) |
| Addiction | Phase II | OX1R antagonism reduces drug-seeking |
| Depression | Phase II | Orexin system dysregulation |
- Approach: DSIP analogs or GABAergic potentiators
- Challenges: Receptor characterization incomplete
- Current agents: No approved DSIP agonists
- Research tools: DSIP fragments, synthetic analogs
| Agent | Selectivity | Indication | Status |
|---|
| Suvorexant | Dual OX1R/OX2R | Insomnia | FDA-approved |
| Lemborexant | Dual OX1R/OX2R (OX2R-preferred) | Insomnia | FDA-approved |
| Daridorexant | Dual OX1R/OX2R | Insomnia | FDA-approved |
| Almorexant | Dual OX1R/OX2R | Insomnia | Discontinued |
| Parameter | Effect | Magnitude |
|---|
| Sleep latency | Decreased | 20–40% |
| SWS duration | Increased | 30–50% |
| Delta power | Increased | 15–30% |
| REM sleep | No change or decreased | 0–10% |
| Total sleep time | Increased | 10–20% |
| Parameter | Effect | Magnitude |
|---|
| Sleep latency | Decreased | 30–50% |
| Wake after sleep onset | Decreased | 30–40% |
| SWS | No change | — |
| REM sleep | No change | — |
| Total sleep time | Increased | 15–25% |
- Sleep disruption: Fragmented SWS, reduced delta power
- Age-related decline: DSIP levels decrease with aging
- Stress-related insomnia: Stress suppresses DSIP release
- Jet lag: Circadian disruption reduces DSIP signaling
- Cause: Autoimmune destruction of orexin neurons
- Prevalence: 1:2,000
- Symptoms: Excessive daytime sleepiness, cataplexy, sleep paralysis
- CSF orexin: <110 pg/mL (diagnostic)
- Treatment: Wake-promoting agents (modafinil, solriamfetol)
| Parameter | Value |
|---|
| Dose | 25–100 µg (research) |
| Route | Intravenous or intranasal |
| Half-life | 10–15 minutes |
| Formulation | Lyophilized powder |
| Stability | Low (peptidase sensitive) |
| Agent | Dose | Half-life | Route |
|---|
| Suvorexant | 10–20 mg | 12 hours | Oral |
| Lemborexant | 5–10 mg | 17–19 hours | Oral |
| Daridorexant | 25–50 mg | 8–10 hours | Oral |
| Feature | DSIP | Orexin |
|---|
| Size | 9 aa | 33 aa (A) / 28 aa (B) |
| MW | 849 Da | 3,562 Da (A) |
| Function | Sleep promotion | Wake promotion |
| Mechanism | GABAergic modulation | Excitatory arousal signaling |
| Brain location | Thalamus, hypothalamus | Lateral hypothalamus |
| Receptor | Putative GPCR | OX1R, OX2R |
| Receptor clarity | Low | High |
| Approved drugs | None | Suvorexant, lemborexant |
| Clinical stage | Phase II | Approved (antagonists) |
- Schoenenberger GA, Monnier M. “Characterization of a delta-electroencephalogram-(sleep)-inducing peptide.” Proc Natl Acad Sci 1977;74:1282-1286.
- Sakurai T, et al. “Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors.” Cell 1998;92:573-585.
- Kukkonen JP, et al. “Orexin/hypocretin signaling.” Curr Top Med Chem 2012;12:1-23.
- Hoyer D, Jacobson LH. “Orexin in sleep, insomnia and beyond.” Neurotherapeutics 2020;17:1-12.
- Mieda M, Sakurai T. “Orexin deficiency and narcolepsy.” Curr Top Dev Biol 2019;133:171-190.
